Zacks: Analysts Anticipate Syneos Health, Inc. (NASDAQ:SYNH) Will Announce Quarterly Sales of $1.19 Billion

Wall Street brokerages expect that Syneos Health, Inc. (NASDAQ:SYNH) will report sales of $1.19 billion for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Syneos Health’s earnings. The highest sales estimate is $1.23 billion and the lowest is $1.18 billion. Syneos Health reported sales of $1.16 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 2.6%. The firm is expected to report its next earnings report on Thursday, April 29th.

According to Zacks, analysts expect that Syneos Health will report full-year sales of $5.22 billion for the current year, with estimates ranging from $5.19 billion to $5.25 billion. For the next fiscal year, analysts anticipate that the company will post sales of $5.63 billion, with estimates ranging from $5.56 billion to $5.68 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Syneos Health.

Syneos Health (NASDAQ:SYNH) last posted its quarterly earnings results on Thursday, February 18th. The company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. Syneos Health had a net margin of 4.28% and a return on equity of 10.02%.

A number of equities research analysts have recently commented on the stock. TheStreet upgraded shares of Syneos Health from a “c+” rating to a “b-” rating in a report on Monday, November 30th. Mizuho raised their target price on shares of Syneos Health from $72.00 to $87.00 and gave the stock a “buy” rating in a report on Monday. Citigroup raised their target price on shares of Syneos Health from $80.00 to $85.00 in a report on Friday. Smith Barney Citigroup raised their target price on shares of Syneos Health from $75.00 to $80.00 in a report on Wednesday, December 9th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their target price on shares of Syneos Health from $75.00 to $80.00 in a report on Wednesday, December 9th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Syneos Health has a consensus rating of “Buy” and an average target price of $73.31.

In related news, Director Thomas H. Lee Advisors, Llc sold 627 shares of the firm’s stock in a transaction on Thursday, December 3rd. The shares were sold at an average price of $61.28, for a total transaction of $38,422.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jason M. Meggs sold 4,062 shares of the firm’s stock in a transaction on Friday, November 27th. The shares were sold at an average price of $67.00, for a total transaction of $272,154.00. Following the transaction, the chief financial officer now directly owns 66,003 shares of the company’s stock, valued at $4,422,201. The disclosure for this sale can be found here. Insiders have sold a total of 3,313,515 shares of company stock worth $204,210,569 over the last 90 days. Insiders own 0.44% of the company’s stock.

Large investors have recently modified their holdings of the business. Prospera Financial Services Inc purchased a new position in shares of Syneos Health during the 3rd quarter worth about $48,000. Harbor Investment Advisory LLC boosted its stake in shares of Syneos Health by 91.6% during the 3rd quarter. Harbor Investment Advisory LLC now owns 1,004 shares of the company’s stock worth $53,000 after purchasing an additional 480 shares during the period. AJO LP purchased a new position in shares of Syneos Health during the 4th quarter worth about $72,000. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of Syneos Health by 50.6% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,286 shares of the company’s stock worth $88,000 after purchasing an additional 432 shares during the period. Finally, LSV Asset Management purchased a new position in shares of Syneos Health during the 3rd quarter worth about $148,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:SYNH traded down $0.90 during trading on Tuesday, reaching $73.11. 452,690 shares of the stock traded hands, compared to its average volume of 661,983. The stock has a 50-day moving average of $75.82 and a two-hundred day moving average of $64.86. Syneos Health has a 52-week low of $30.02 and a 52-week high of $81.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a market cap of $7.63 billion, a P/E ratio of 40.66 and a beta of 1.85.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.